ScreenerHero
HROWHarrow Health, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · harrow.com
41.71USD+0.16%Mkt Cap: 1.56B $P/E: —

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segment…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.56B $
Enterprise Value1.79B $
Revenue (TTM)275.59M $
Gross Profit204.37M $
Net Income (TTM)-5.14M $
Revenue/Share7.398 USD
Last Price41.71 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees373
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)15.37
PEG—
EV/EBITDA101.15
EV/Revenue6.50
P/S5.72
P/B103.60
EPS (TTM)-1.00
EPS (Forward)2.74
52W Range
28.5450% of range54.85
52W High54.85 USD
52W Low28.54 USD
Profitability
Gross Margin75.05%
Oper. Margin-15.58%
EBITDA Margin6.43%
Profit Margin-1.89%
ROE-9.80%
ROA-1.29%
Growth
Revenue Growth10.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF43.86M $
CapEx (TTM)1.10M $
FCF Margin-1.99%
FCF Yield-0.35%
Net Debt215.43M $
Net Debt/EBITDA12.16
Balance Sheet
Debt/Equity4.80
Current Ratio2.24
Quick Ratio2.00
Book Value/Sh0.4060 USD
Cash/Share2.276 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateFeb 8, 2013
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)67.50 USD
Upside (mean)+61.9%
Target Range59.00 USD – 88.00 USD
$59.00+61.9% to mean$88.00
# Analysts8
Ownership
Shares Out.37.49M
Float28.93M
Insiders15.38%
Institutions58.60%
Short Interest
Short Ratio11.5d
Short % Float20.14%
Short % Out.18.10%
Shares Short6.78M
Short (prev mo.)7.15M
Technical
SMA 5041.15 (+1.3%)
SMA 20041.18 (+1.3%)
Beta0.25
S&P 52W Chg18.16%
Avg Vol (30d)554.99K
Avg Vol (10d)721.92K
Technical Indicators
RSI (14)55.7
MACD-0.2070
MACD Signal-0.3129
MACD Hist.+0.1059
BB Upper42.26 USD
BB Middle39.73 USD
BB Lower37.19 USD
BB Width12.78%
ATR (14)2.147 USD
Vol Ratio (20d)1.19x